Navigation Links
Osteotech Completes Tissue Supply Agreement With LifeNet Health
Date:10/16/2007

EATONTOWN, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE) announced today that it has entered into a tissue supply agreement with LifeNet Health, Inc. Pursuant to the agreement, LifeNet Health will provide Osteotech with tissue which will be utilized by Osteotech for its core DBM, Biocomposite and Collagen Technologies. The agreement was effective September 1, 2007, has an initial five-year term which can be terminated earlier by either party on six months notice, and automatically renews for successive two-year terms unless terminated by either party six months prior to renewal. Osteotech currently has an agreement with LifeNet Health and its distribution partner, Depuy Spine, for the processing and distribution of a private label DBM.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, commented, "We are extremely pleased to have expanded our relationship with LifeNet Health. We respect and support LifeNet Health's commitment to saving lives and restoring health. LifeNet Health has an excellent reputation and their commitment to tissue donation is outstanding."

Mr. Owusu-Akyaw continued, "Our tissue supply arrangements with LifeNet Health and Community Tissue Services provide a strong foundation for our tissue needs in future years. We will continue to pursue our strategic initiatives to establish additional relationships with other tissue recovery organizations and tissue banks."

LifeNet Health, founded in 1982, is a full service biomedical tissue banking system and a leading non-profit organ and tissue donation agency whose mission is saving lives and restoring health. LifeNet Health provides recovery and processing services for musculoskeletal and cardiovascular tissues, distributing more than 225,000 biomedical implants every year to restore health to patients around the world.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions to surgeons and patients for the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com .

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of October 17, 2007 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. iGATE Completes Phase I Testing Of Meningitis Vaccine
2. Delhi Hospital Completes 100 Liver Transplants
3. Roche Completes Acquisition of BioVeris
4. New drug to treat Heart Attack and damaged tissue
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. Leeches help in tissue transfer
7. Bone marrow stem cells may help repair cardiac tissues
8. Free Tissue Transfer Effective in Treating Massive Skin Cancers
9. Tissue Transfer for Skin Cancer
10. Tissue Transfer For Treatment Of Massive Skin Cancers
11. Loss Of Brain Tissue Linked To Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology: